# Medtronic **Entity class:** Medical-technology company **Domain:** Neuromodulation / Implantable Devices **Doc Type:** Company Node **Maturity:** Developing **Collection:** [[collections/Neurotech|Neurotech]] **Primary Sources:** [[research/Research Inferences|Research Inferences]] (INF-0061 to INF-0068); [[research/Research Inferences Integration Report - 2026-10-23|Research Inferences Integration Report — 2026-10-23]] ## Definition **Medtronic is the medical-device manufacturer whose Percept deep-brain-stimulation platform is the largest installed base of sensing brain implants in the world.** More than 40,000 patients carry Percept neurostimulators (company figure, February 2025), and on 24 February 2025 the FDA approved [[wiki/BrainSense Adaptive DBS|BrainSense Adaptive DBS]], which runs on that installed base and adjusts stimulation in real time from the patient's own brain signals. Medtronic called it the largest commercial launch of brain-computer-interface technology to date. ## Neuromodulation portfolio relevant to the corpus - **Percept PC and Percept RC** neurostimulators with BrainSense sensing of local field potentials. - **[[wiki/BrainSense Adaptive DBS|BrainSense Adaptive DBS]]** (aDBS): closed-loop stimulation for Parkinson's disease, activated by a software update to an already-implanted Percept device, with no further surgery. - **BrainSense Electrode Identifier:** automated electrode selection that shortens initial programming. ## Forward Capability Medtronic converts an installed medical-device fleet into a closed-loop brain-computer interface by shipping software. Every Percept patient is a potential adaptive-loop patient, which makes the company's firmware cadence the fastest-moving variable in deployed BCI. The register's reading is that the sensing hardware generalizes to any condition with a detectable neural signature, so the fleet is a general-purpose neural observatory with one approved use and many latent ones. Medtronic is also reported as a partner of [[wiki/Precision Neuroscience|Precision Neuroscience]]; the terms were unconfirmed at this writing. ## Open Questions - The 2026 count of Percept and aDBS patients, from investor materials. - Additional indications for adaptive sensing beyond Parkinson's disease. - Fleet data practices: what fraction of recorded neural data is retained or used for model development (INF-0072). ## Research Inferences These entries translate the forward-looking register in [[research/Research Inferences|Research Inferences]] into ordinary wiki prose. The tier labels apply to the inference, not automatically to every factual anchor inside it. Proposed IDs above INF-0500 and tier recommendations come from the 2026-10-23 cycle: [[research/Research Inferences Integration Report - 2026-10-23|Research Inferences Integration Report — 2026-10-23]] · [[research/Research Inferences Integration Audit - 2026-10-23|Research Inferences Integration Audit — 2026-10-23]]. - **INF-0061 — Established.** More than 40,000 patients carry Medtronic Percept devices, making adaptive DBS the largest commercial deployment of brain-computer interface technology that has ever existed. The installed base of sensing neural implants is already measured in tens of thousands, and it is clinical rather than experimental. - **INF-0067 — Strongly indicated.** Once a neural biomarker is validated for one condition, the sensing hardware generalizes to any condition with a detectable spectral signature. The installed Percept base is therefore a general-purpose neural observatory with a single approved use and many latent ones. - **INF-0363 — Analytic.** Tens of thousands of sensing implants under one manufacturer's management constitute a fleet with firmware versions, telemetry, and rollout policy. Fleet management practices from software operations now apply to a population of human nervous systems. - **INF-0492 — Strongly indicated.** Once tens of thousands of people carry sensing implants, the infrastructure, workforce, and regulatory habits exist and do not disappear. Installed base is what makes a trajectory irreversible, and it is already established for neural sensing. - **INF-0495 — Analytic.** The largest deployment of brain-computer interface technology is a movement-disorder therapy that almost nobody counts as a BCI. Category framing determines what is noticed, and the most consequential deployments are routinely filed under other names. ## Relationships - **manufactures:** [[wiki/BrainSense Adaptive DBS|BrainSense Adaptive DBS]] (FDA approval 24 February 2025) on the Percept platform. - **indication:** [[wiki/Parkinson's Disease|Parkinson's Disease]]. - **cluster_home:** [[wiki/Distributed Biological Interfaces|Distributed Biological Interfaces]] (INF-0061 to INF-0068) · [[wiki/Closed-Loop Neuromodulation|Closed-Loop Neuromodulation]]. - **reported_partner:** [[wiki/Precision Neuroscience|Precision Neuroscience]]. - **category_peer:** [[wiki/Neuralink|Neuralink]], [[wiki/Synchron|Synchron]], [[wiki/Paradromics|Paradromics]] (investigational BCIs with far smaller implanted populations). - **ecosystem:** [[wiki/Brain-Computer Interfaces|Brain-Computer Interfaces]] · [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] · [[collections/Neurotech|Neurotech]]. ## Sources - [Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system — Medtronic, 24 February 2025](https://news.medtronic.com/2025-02-24-Medtronic-earns-U-S-FDA-approval-for-the-worlds-first-Adaptive-deep-brain-stimulation-system-for-people-with-Parkinsons) - [Medtronic earns US FDA approval of "world's first" adaptive DBS system — NeuroNews International, February 2025](https://neuronewsinternational.com/medtronic-earns-us-fda-approval-of-worlds-first-adaptive-dbs-system-for-parkinsons/) - [Chronic adaptive deep brain stimulation in Parkinson's disease: ADAPT-START findings — npj Parkinson's Disease, 2026](https://www.nature.com/articles/s41531-026-01269-z) As of 23 October 2026.